SCHEMBL4818347

SCHEMBL4818347

[CH2]CCc1ccnc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.60
NCF1 P14598 1/20 0.48
HTR1A P08908 2/20 0.47
ADRA1D P25100 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA1B P35368 2/20 0.47
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
HIF1A Q16665 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FERMT2 Q96AC1 1/20 0.42
MAPT P10636 2/20 0.41
CYP19A1 P11511 1/20 0.41
TBXAS1 P24557 1/20 0.41
PTPN1 P18031 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870247 0.89 LOXL2 (0.56) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL5541655 0.87 LOXL2 (0.55) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL5537149 0.86 CYP19A1 (0.54) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL16289396 0.85 LOXL2 (0.53) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL16288899 0.85 LOXL2 (0.53) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL5542236 0.85 LOXL2 (0.53) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL7767284 0.85 LOXL2 (0.53) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL3817375 0.83 LOXL2 (0.64) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL2333461 0.82 LOXL2 (0.62) LOXL2NCF1HTR1AADRA1DADRA1A
SCHEMBL2331919 0.82 LOXL2 (0.62) LOXL2NCF1HTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
EP-1642901-B1 Novel erythromycin derivatives PFIZER PROD INC (US) 2007-10-31 EP claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
EP-1642901-A1 Novel erythromycin derivatives Pfizer Products Inc. (US) 2006-04-05 EP claimed
US-20050209446-A1 Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these MEIJI SEIKA KAISHA LTD. (JP) 2005-09-22 US claimed
CN-1639181-A Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these MEIJI SEIKA KAISHA (JP) 2005-07-13 CN claimed
US-6825171-B2 MACROLIDE ANTIBIOTIC USEFUL IN THE TREATMENT OF A BROAD SPRECTRUM OF BACTERIAL INFECTIONS AND PROTOZOA INFECTIONS PFIZER, INC. 2004-11-30 US claimed
EP-1479687-A1 NOVEL 15-MEMBERED CYCLIC AZALIDE, NOVEL 16-MEMBERED CYCLIC DIAZALIDE DERIVATIVE, AND PROCESS FOR PRODUCING THESE MEIJI SEIKA KAISHA LTD. (JP) 2004-11-24 EP claimed
US-20040067897-A1 Novel erythromycin derivatives PFIZER INC. 2004-04-08 US claimed
WO-2000010985-A1 ENANTIOSELECTIVE CHIRAL SULPHIDE CATALYSTS AND A METHOD FOR THE MANUFACTURE THEREOF NESTE CHEMICALS OY (FI) 2000-03-02 WO claimed
WO-1999062920-A1 TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN PFIZER PRODUCTS INC. (US) 1999-12-09 WO claimed
EP-0952157-A1 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin Pfizer Products Inc. (US) 1999-10-27 EP claimed
CN-1224426-A 3-descladinose-2, 3-anhydroerythromycin derivatives ABBOTT LAB (US) 1999-07-28 CN claimed
WO-1999035157-A1 NOVEL ERYTHROMYCIN DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-07-15 WO claimed
EP-0922050-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-06-16 EP claimed
WO-1999021865-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-05-06 WO claimed
US-5750510-A ANTIBIOTICS ABBOTT LABORATORIES (US) 1998-05-12 US claimed
WO-1997042205-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1997-11-13 WO claimed
EP-0008962-B1 4-(4-QUINOLYLPROPYL)PIPERIDINE DERIVATIVES AND PHARMACEUTICALS CONTAINING THEM PHARMUKA LABORATOIRES (FR) 1983-02-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209446-A1 Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these PRMT9, DHRS9, MRPL9 LOXL2 4122/4885NCF1 1690/4885HTR1A 4086/4885
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 LOXL2 4109/4885NCF1 85/4885HTR1A 2932/4885
US-20040067897-A1 Novel erythromycin derivatives GIPR, MLNR, PGC LOXL2 4313/4885NCF1 3382/4885HTR1A 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.